Op2Lysis develops drugs for hemorrhagic stroke patients.
Op2Lysis has raised $2.9M in total funding. The most recent round was Grant. The last funding was announced in October 2021.
Op2Lysis's investors include European Innovation Council.
Op2Lysis is headquartered in Boulogne-billancourt, France.
Op2Lysis develops drugs for hemorrhagic stroke patients.
Op2Lysis is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Op2Lysis — Funding & Investors." VCBacked, October 6, 2021, https://www.vcbacked.co/company/op2lysis. Accessed July 22, 2026.
VCBacked. (2021). Op2Lysis — Funding & Investors. Retrieved July 22, 2026, from https://www.vcbacked.co/company/op2lysis
{{cite web |title=Op2Lysis — Funding & Investors |url=https://www.vcbacked.co/company/op2lysis |website=VCBacked |access-date=July 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated